An abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP) has been accepted for a poster presentation at ASGCT 2021 Annual Meeting, to be held virtually on 11-14 May.

 

Paris, April 15, 2021 – SparingVision (the “Company”), a genomic medicines company developing vision saving treatments for ocular diseases, today announces that an abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP) has been accepted for a poster presentation at ASGCT 2021 Annual Meeting, to be held virtually on 11-14 May (details and timing of the presentation below). The poster was developed in the laboratory of Dr. McCall of University of Louisville, Kentucky, SparingVision’s academic collaborators. SparingVision’s novel approach to treat RP and other rod-cone dystrophies, SPVN06, introduces rod-derived cone viability factors in order to prevent degeneration of photoreceptors in the retina.

Title: Rod-Derived Cone Viability Factor Provides Trophic Support for Cone Photoreceptors in a Pig Model of Retinitis Pigmentosa

Date and Time: Tuesday May 11th 2021, 8:00 AM - 10:00 AM EST

Presenter: Dr. Jennifer Noel, University of Louisville

Session Title: Neurologic Diseases

Abstract #: 552

The abstract will also be published on the ASGCT website from 4:30 PM EST on April 27th.

 

**ENDS**

 
 
NOTES TO EDITORS:
 
About SparingVision:
SparingVision is a genomic medicines company, translating pioneering science into vision saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific foundersat the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is SPVN06, a gene independent treatment for retinitis pigmentosa (RP), the most common inherited retinal disease affecting two million people worldwide. SPVN06 could form the basis of a suite of new sight saving treatments as it could be applicable to many other retinal diseases, regardless of genetic cause.
 
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
 
About SPVN06:
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision’s primary disease target is Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases where the loss of rods is known to be an early signal of the disease. First-in-man trials, with SPVN06 in patientswith RP, will be commencing in 2021.